Drugs / Puterizumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06434740 | Jun 2024 → Dec 2026 expected | non-small cell lung carcinoma | Sir Run Run Shaw Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Puterizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06434740 ↗ |
| Route | Intravenous | “intravenous infusion” NCT06434740 ↗ |